Skip to main content

BPC-157 & TB-500 vs IGF-1 LR3

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

BPC-157 & TB-500

Known as the 'Wolverine Stack,' this popular combination pairs two powerful healing peptides. BPC-157 and TB-500 work synergistically to promote tissue repair, reduce inflammation, and accelerate recovery from injuries.

Full details →

IGF-1 LR3

IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a modified version of IGF-1 with extended half-life and enhanced potency. The modifications prevent binding to IGF binding proteins, increasing bioavailability.

Full details →

Side-by-Side Comparison

AspectBPC-157 & TB-500IGF-1 LR3
MechanismBPC-157 upregulates growth factor expression and promotes angiogenesis, while TB-500 promotes cell migration and differentiation through actin regulation. Together, they enhance wound healing, reduce scar tissue formation, and support musculoskeletal recovery through complementary pathways.Binds to IGF-1 receptors to promote protein synthesis, muscle growth, and fat metabolism. The LR3 modification (13 amino acid extension and arginine substitution) extends half-life from minutes to 20-30 hours.
Typical DosageTypical research protocols: BPC-157 at 250-500mcg daily combined with TB-500 at 2-2.5mg twice weekly during loading phase, then 2mg every 2 weeks for maintenance.Research protocols typically use 20-100mcg daily, often divided into multiple injections or administered bilaterally to target muscles.
AdministrationBoth peptides administered via subcutaneous injection. Some protocols suggest injecting near injury sites for localized effects. Can be injected separately or as a pre-mixed blend.Intramuscular injection (site-specific growth) or subcutaneous for systemic effects. Often cycled 4-6 weeks on, equal time off.
Side EffectsGenerally well-tolerated. May include mild nausea, temporary fatigue, headache, or localized irritation at injection sites.Hypoglycemia, joint pain, water retention, potential jaw/hand growth with extended use, and injection site reactions.
Best For

What They Have in Common

Both BPC-157 & TB-500 and IGF-1 LR3 are commonly used for:

Key Differences

Unique to IGF-1 LR3:

Ready to Learn More?